作者
Jawad H Butt, Pardeep S Jhund, Jan Belohlávek, Rudolf A de Boer, Chern-En Chiang, Akshai S Desai, Jarosław Drożdż, Adrian F Hernandez, Silvio E Inzucchi, Tzvetana Katova, Masafumi Kitakaze, Mikhail N Kosiborod, Carolyn SP Lam, Anna Maria Langkilde, Daniel Lindholm, Erasmus Bachus, Felipe Martinez, Béla Merkely, Magnus Petersson, Jose F Kerr Saraiva, Sanjiv J Shah, Muthiah Vaduganathan, Orly Vardeny, Ulrica Wilderäng, Brian C Claggett, Scott D Solomon, John JV McMurray
发表日期
2022/10/18
期刊
Circulation
卷号
146
期号
16
页码范围
1210-1224
出版商
Lippincott Williams & Wilkins
简介
Background
Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure).
Methods
Frailty was measured using the Rockwood cumulative deficit approach. The primary end point was time to a first worsening heart failure event or cardiovascular death.
Results
Of the 6263 patients randomized, a frailty index (FI) was calculable in 6258. In total, 2354 (37.6%) patients had class 1 frailty (FI ≤0.210; ie, not frail), 2413 (38.6%) had class 2 frailty (FI 0.211–0.310; ie, more frail), and 1491 (23.8%) had …
学术搜索中的文章
JH Butt, PS Jhund, J Belohlávek, RA De Boer… - Circulation, 2022